Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story
Catalyst Pharmaceuticals has agreed to an all-cash acquisition by Angelini Pharma and settled all Firdapse patent litigation, granting generic licenses through 2035. This deal provides an exit strategy for current public shareholders and positions Catalyst’s rare disease portfolio within a larger pharmaceutical group, changing its narrative from independent growth to integration. Investors should monitor transaction terms, closing timelines, and how the combined entity will position its rare disease portfolio.
Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX)
This article provides a list of recent news headlines, press releases, and research articles related to Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX). It covers financial results, analyst ratings, acquisition news, patent litigation settlements, and conference participations, spanning from December 2025 to May 2026. The stock was trading at 31.18, up 0.02 (+0.06%) as of 4:00 PM EDT, May 15, 2026.
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y
Catalyst Pharmaceuticals reported first-quarter earnings that surpassed expectations, with Firdapse revenues showing year-over-year growth. This financial performance indicates a positive start to the year for the company, largely driven by its key drug.
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus
Angelini Pharma is reportedly considering an acquisition of Catalyst Pharmaceuticals (NasdaqCM:CPRX), focusing attention on Catalyst's rare disease portfolio and market valuation. While early discussions are underway and Angelini is exploring other targets, this potential deal highlights Catalyst's attractiveness and could significantly impact its share price depending on the certainty of funding and deal terms. Investors are advised to monitor official confirmations and how the share price reacts to periods of silence, as the current valuation may reflect M&A expectations.
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives
Catalyst Pharmaceuticals (CPRX) reported strong Q1 2026 results with revenues of US$149.4 million and EPS of US$0.52, maintaining a high net profit margin of 37.1%. While bullish narratives highlight durable margins from rare disease drugs like FIRDAPSE and AGAMREE, concerns exist regarding slower earnings growth (12.1% annually against 32.6% over five years) and heavy reliance on a few key products, which could face competition and pressure future profitability. The stock currently trades at a P/E of 17.2x, below the industry average and a DCF fair value of US$64.46, leading to a split in investor sentiment.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Catalyst Pharmaceuticals reported strong Q1 2026 earnings, beating analyst estimates with adjusted earnings of 79 cents per share and total revenues of $149.4 million. The growth was primarily driven by Firdapse sales, which increased 18% year over year, and the newer drug Agamree. The company also announced a settlement for Firdapse patent litigation and is set to be acquired by Angelini Pharma for approximately $4.1 billion, reinforcing Angelini's focus on neurological diseases.
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65
Catalyst Pharmaceuticals, Inc. (CPRX) announced its Q1 adjusted earnings per share (EPS) of $0.79, significantly exceeding FactSet's estimate of $0.65 per share. This financial performance indicates a stronger-than-anticipated quarter for the company.
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M
Catalyst Pharmaceuticals, Inc. (CPRX) reported its Q1 revenue at $149.4 million, slightly below FactSet's estimate of $149.5 million. The company is a biopharmaceutical firm focused on developing medicines for rare and difficult-to-treat diseases, marketing products like FIRDAPSE, FYCOMPA, and AGAMREE. This earnings flash provides a quick overview of their financial performance for the first quarter.
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Catalyst Pharmaceuticals reported strong first-quarter 2026 financial results, with total Q1 2026 net product revenue reaching $149.3 million, a 5.6% year-over-year increase. The growth was primarily driven by FIRDAPSE® and AGAMREE®, which saw revenue increases of 18.1% and 66.6% respectively. The company also reported $755.9 million in cash and cash equivalents and no funded debt as of March 31, 2026.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is examining whether the offering price of $31.50 per share adequately values the company and if the process leading to the transaction was fair to shareholders. Shareholders are encouraged to contact KSF to discuss their legal rights regarding the proposed sale.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum
Catalyst Pharmaceuticals (CPRX) has shown strong share price momentum recently. The stock trades at a P/E of 17.8x, which is considered good value against peers but slightly expensive compared to its estimated fair P/E of 15.1x. A Discounted Cash Flow (DCF) model suggests a fair value almost double the current price, indicating a potential significant undervaluation.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash. KSF is scrutinizing whether this acquisition price and the process leading to it adequately value the company. Shareholders who believe the transaction undervalues Catalyst Pharmaceuticals are encouraged to contact KSF to discuss their legal rights.
Angelini Pharma buying Catalyst (NASDAQ: CPRX) in $4.1B all-cash deal at premium
Angelini Pharma will acquire Catalyst Pharmaceuticals (NASDAQ: CPRX) in an all-cash deal valued at approximately $4.1 billion, or $31.50 per share, representing a significant premium. This acquisition marks Angelini Pharma's entry into the U.S. market, aiming to strengthen its presence in brain health and rare diseases. Additionally, Catalyst settled patent litigation for its drug FIRDAPSE®, securing U.S. market exclusivity for its generic version until January 2035.
SEC Form DEFA14A filed by Catalyst Pharmaceuticals Inc.
This article reports that Catalyst Pharmaceuticals Inc. has filed an SEC Form DEFA14A, as tracked by Quantisnow. Quantisnow is highlighted as a real-time market data platform that aggregates various financial information for retail investors. The report also lists recent analyst ratings for CPRX and related news and SEC filings concerning the company.
Catalyst drops May 12 earnings webcast after Angelini acquisition news
Catalyst Pharmaceuticals (Nasdaq: CPRX) has canceled its Q1 2026 earnings conference call and webcast, previously scheduled for May 12, 2026, due to a pending acquisition by Angelini Pharma S.p.A. The company will still release its first-quarter financial results after market close on Monday, May 11, 2026, as planned. This cancellation means investors will not have the opportunity for a live Q&A session with management.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) stock rose 2.11% to $31.17 on Thursday, despite a generally poor trading day for the broader market, with both the NASDAQ Composite and Dow Jones Industrial Average falling. This performance places CPRX just 4.28% shy of its 52-week high achieved on April 27th. The article highlights the company's strong individual stock performance against a backdrop of market decline.
Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1B
This article reports on Angelini Pharma's intent to acquire Catalyst Pharmaceuticals for $4.1 billion. The acquisition highlights a significant move in the pharmaceutical industry, consolidating assets and potentially expanding market reach for the combined entity.
Angelini Pharma’s $3.9b Cash Deal Caps Catalyst Pharmaceuticals Upside Risks
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $3.9 billion in an all-cash deal, capping the near-term upside for Catalyst shareholders at $31.50 per share. The acquisition shifts Catalyst's narrative from an independent growth company to a finite cash exit, highlighting deal-specific risks like regulatory approval and the absence of competing bids. The transaction, backed by Blackstone and BNP Paribas, is expected to close in Q3 2026, offering shareholders a defined timeline for monetizing their investment.
Catalyst Pharmaceuticals and Hetero Labs Ltd. Settle FIRDAPSE Patent Litigation; Hetero to Market Generic Version Starting January 2035
Catalyst Pharmaceuticals and Hetero Labs Ltd. have reached a settlement in their patent litigation concerning the generic version of FIRDAPSE. Under the agreement, Hetero Labs can market its generic FIRDAPSE in the U.S. starting in January 2035, subject to FDA approval and other conditions. This settlement resolves all outstanding patent disputes related to FIRDAPSE, providing market clarity for Catalyst Pharmaceuticals.
Generic FIRDAPSE delayed until Jan. 2035 as Catalyst ends last patent case
Catalyst Pharmaceuticals and its licensor SERB have settled patent litigation with Hetero Labs Ltd. regarding a generic version of FIRDAPSE (amifampridine) 10 mg tablets. The agreement prevents Hetero from marketing its generic in the U.S. before January 2035, pending FDA approval, and resolves all remaining FIRDAPSE patent litigation for Catalyst. The confidential settlement will be submitted to the U.S. FTC and DOJ for review.
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Angelini Pharma is set to acquire Catalyst Pharmaceuticals for approximately $4.1 billion (3.5 billion Euros), marking its entry into the U.S. market and strengthening its focus on Brain Health and Rare Diseases. The acquisition, approved by both companies' boards, is expected to close in the third quarter of 2026. This move will integrate Catalyst's rare disease product portfolio, including FIRDAPSE®, AGAMREE®, and FYCOMPA®, with Angelini Pharma's expertise, aiming to create a significant global player in neurological rare diseases.
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Angelini Pharma is set to acquire Catalyst Pharmaceuticals for $4.1 billion ($3.5 billion Euros), a move that will mark Angelini Pharma's entry into the U.S. market. The acquisition, unanimously approved by both companies' boards, aims to strengthen Angelini Pharma's leadership in brain health and rare diseases by integrating Catalyst's robust portfolio of products. This strategic transaction, expected to close in the third quarter of 2026, will create a next-generation therapeutic platform especially focused on rare neurological diseases.
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors
Catalyst Pharmaceuticals Inc. (CPRX) stock decreased by 1.10% to $30.52 on Wednesday, underperforming the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average, which saw gains. This decline broke a three-day winning streak for the company's shares.
Catalyst Pharmaceuticals (Nasdaq:CPRX) - Stock Analysis
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) is a commercial-stage biopharmaceutical company focused on rare diseases. The stock is currently valued at US$31.17, with analysts targeting US$34.29, suggesting it is 9.1% undervalued. Recent news indicates Angelini Pharma is acquiring Catalyst Pharmaceuticals for approximately US$4.1 billion, with the deal expected to close in Q3 2026.
Is Catalyst Pharmaceuticals (CPRX) Share Price Rally Still Supported By Cash Flow Outlook?
Catalyst Pharmaceuticals' stock (CPRX) has seen significant rallies over the past year, prompting a valuation analysis. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 52.1% with an intrinsic value of $64.47 per share, while a Price-to-Earnings (P/E) ratio comparison indicates it might be overvalued when compared to Simply Wall St's proprietary Fair Ratio. Investors are encouraged to use "Narratives" to align their personal investment theses with financial forecasts and price targets.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Catalyst Pharmaceuticals Inc. (CPRX) advanced 6.63% to $30.86, outperforming competitors and the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average. This marks the stock's third consecutive day of gains. The positive movement occurred during a favorable trading session for the overall stock market.
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
Catalyst Pharmaceuticals (CPRX) is anticipated to surpass its first-quarter 2026 earnings estimates, with expected EPS of 64 cents and revenues of $147.1 million. The company's key product, Firdapse, is projected to see increased sales, while Fycompa sales may decline due to patent expirations. Agamree, another drug for Duchenne Muscular Dystrophy, is also expected to contribute positively to sales.
Hussman Strategic Advisors Inc. Sells 42,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
Hussman Strategic Advisors Inc. reduced its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 28.6% in the fourth quarter, selling 42,000 shares and now holding 105,000 shares valued at approximately $2.45 million. Despite this sale, analyst sentiment remains strong, with a consensus "Strong Buy" rating and an average price target of $34.00 for CPRX. The company's stock recently traded at $28.74, boasting a market cap of $3.51 billion and a P/E ratio of 17.01.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock rise by 2.17% to $28.74 on Friday, outperforming competitors despite a mixed broader market. This advance ended a two-day losing streak for the company. The NASDAQ Composite Index increased by 0.89%, while the Dow Jones Industrial Average declined by 0.31%.
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus
Angelini Pharma is reportedly considering acquiring Catalyst Pharmaceuticals (NasdaqCM:CPRX), sparking interest in the rare disease value of Catalyst. The potential acquisition could broaden Angelini Pharma's reach beyond Europe and enhance Catalyst's existing portfolio, though discussions are in early stages and uncertain. Investors are advised to monitor official confirmations and how the stock price reacts, as a significant portion of its current valuation is linked to M&A expectations.
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus
Angelini Pharma is reportedly exploring an acquisition of Catalyst Pharmaceuticals (NasdaqCM:CPRX), focusing attention on the value of Catalyst's rare disease portfolio. While discussions are in early stages and Angelini is considering other targets, a potential deal could expand Angelini's presence in the US and offers Catalyst shareholders a chance for a re-evaluation of control and asset worth. Investors should monitor developments like upcoming earnings calls for confirmation and details on deal terms.
Universal Beteiligungs und Servicegesellschaft mbH Has $3.91 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX
Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 30% during the fourth quarter, now holding 167,763 shares valued at $3.91 million. Institutional investors collectively own 79.22% of the company, which has a market cap of $3.45 billion. Analysts currently have an average "Strong Buy" rating with a consensus price target of $34.00 for CPRX.
Executive pay, ownership and governance detailed in Catalyst (NASDAQ: CPRX) 2025 10-K/A
Catalyst Pharmaceuticals Inc. (CPRX) filed an amended 2025 annual report (10-K/A) to provide detailed information on directors, executive officers, corporate governance, executive compensation, and security ownership. The amendment clarifies that no financial statements were added and previously reported results remain unchanged. Key figures from the filing include 2025 net product revenue of $588.8 million, net income of $214.3 million, and a CEO total compensation of $8.18 million with a pay ratio of 26:1.
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma
Catalyst Pharmaceuticals (CPRX) saw its stock jump following a report of acquisition interest from Angelini Pharma, an Italian pharmaceutical company. This news suggests a potential takeover bid for Catalyst, known for its focus on neurology and rare diseases.
Catalyst Pharmaceuticals jumps on report of interest from Angelini Pharma
Shares of Catalyst Pharmaceuticals surged following reports that Italy's Angelini Pharma is exploring a potential acquisition of the company. The news highlights a possible strategic move within the pharmaceutical sector.
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday
Catalyst Pharmaceuticals (CPRX) is expected to report its Q1 2026 earnings after market close on Wednesday, May 6th, with analysts forecasting an EPS of $0.63 and revenue of $147.25 million. The company has a "Strong Buy" consensus rating from analysts, with an average target price of $34.00, and institutional investors hold a significant portion of its stock. An earnings call is scheduled for May 12th at 8:30 AM ET.
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors
Catalyst Pharmaceuticals Inc. (CPRX) stock decreased by 4.01% on Wednesday, closing at $28.26. This decline occurred during a mixed trading session where the NASDAQ Composite Index saw a slight gain, while the Dow Jones Industrial Average experienced a drop. The stock's fall ended a two-day winning streak.
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. The company's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the results and provide a business update. Catalyst is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare and difficult-to-treat diseases.
Catalyst posts Q1 results after the bell May 11; call set for 8:30 ET
Catalyst Pharmaceuticals will release its Q1 2026 financial results after market close on May 11, 2026. The company will then host a conference call and webcast on May 12, 2026, at 8:30 AM ET to discuss these results and provide a business update. This announcement comes after a strong 2025 performance and 2026 revenue guidance of $615–$645 million.
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Catalyst Pharmaceuticals, Inc. announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss these results and provide a business update. Details for accessing the conference call and webcast are provided for investors.
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Strong Recent Share Price Gains
This article evaluates Catalyst Pharmaceuticals (CPRX) after recent stock price gains, using a Discounted Cash Flow (DCF) analysis and P/E ratio comparison. The DCF model suggests the stock is significantly undervalued by 53.0%, with an intrinsic value of $62.27 per share against a current price of $29.27. However, based on the P/E ratio, the stock appears slightly overvalued compared to its proprietary "Fair Ratio," although it trades below industry and peer averages.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Catalyst Pharmaceuticals Inc. (CPRX) rose 6.94% to $29.27 on Monday, outperforming the mixed stock market where the NASDAQ Composite Index increased and the Dow Jones Industrial Average fell. The company's stock also hit a new 52-week high, surpassing its previous peak of $28.10.
Catalyst Pharmaceuticals Jumps 6.8% Amid Sector-Wide Rally
Catalyst Pharmaceuticals (CPRX) saw its stock surge by 6.8% to $29.23, participating in a broad rally among biotechnology stocks. The increase was attributed to sector-wide optimism and investor rotation into biotech, rather than company-specific news. While the market capitalization rose to $3.6 billion, investors are advised to monitor the sustainability of the sector's momentum as Catalyst's near-term performance appears tied to broader sentiment.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year High - Here's What Happened
Catalyst Pharmaceuticals (NASDAQ:CPRX) reached a new 52-week high of $27.47, closing at $27.016, following several analyst upgrades to "strong-buy" or "buy" ratings and a consensus target price of $34.00. Citigroup specifically raised its price objective to $35.00. The company, focused on rare neuromuscular diseases with its lead product Firdapse® for LEMS, has a market cap of $3.34 billion and significant institutional ownership.
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock decline by 1.12% to $27.37 on Friday, ending a two-day winning streak. Despite this loss, the stock outperformed the broader market, as the NASDAQ Composite Index rose by 1.63% and the Dow Jones Industrial Average fell by 0.16%.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock rise by 6.71% to $27.68 on Thursday, despite a challenging trading session for the broader market. This marked the second consecutive day of gains for the company, outperforming the NASDAQ Composite and Dow Jones Industrial Average which both experienced declines. The article highlights the strong performance of CPRX amidst a general market downturn.
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com
Catalyst Pharmaceuticals stock reached an all-time high of $26.63, trading within 1% of its 52-week high, driven by a 12.2% total return over the past year and a 25% gain in the last six months. The company's financial strength is highlighted by holding more cash than debt, and its stock appears undervalued based on InvestingPro analysis with a P/E ratio of 15.65 and a PEG ratio of 0.52. Recent strong Q4 2025 financial results, with EPS and revenue significantly exceeding forecasts, and ongoing research into Duchenne muscular dystrophy further contribute to investor confidence.
Catalyst Pharmaceuticals stock hits all-time high at $26.63
Catalyst Pharmaceuticals Inc. (CPRX) stock hit an all-time high of $26.63, reflecting a strong performance with a 12.2% total return over the past year and a 25% gain in the last six months. The company's financial strength is highlighted by holding more cash than debt and exceeding Q4 2025 earnings and revenue forecasts, boosted by strong sales of Firdapse and Agamree. Oppenheimer maintains an Outperform rating with a $33.00 price target as Catalyst continues its research efforts in Duchenne muscular dystrophy.
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Catalyst Pharmaceuticals Inc. stock (CPRX) rose by 1.17% on Wednesday, closing at $25.94. Despite this gain, the stock underperformed the broader market, as both the NASDAQ Composite Index and the Dow Jones Industrial Average saw larger increases. This rise ended a two-day losing streak for Catalyst Pharmaceuticals Inc.
The Bull Case For Catalyst Pharmaceuticals (CPRX) Could Change Following Firdapse Exclusivity Win And Agamree Launch
Catalyst Pharmaceuticals has secured extended U.S. patent exclusivity for its drug Firdapse until 2035 and launched a new muscle disorder therapy, Agamree. These developments could significantly alter the company's investment narrative by reducing revenue concentration risk. While Firdapse's extended exclusivity addresses near-term patent concerns, the company's ability to offset generic competition with new assets like Agamree will be crucial for its future growth and earnings projections.
